Growth Factor Delivery Systems for Tissue Engineering and Regenerative Medicine

Atienza‐Roca, Pau; Cui, Xiaolin; Hooper, G.; Woodfield, Tim B. F.; Lim, Khoon S.

doi:10.1007/978-981-13-0950-2_13

Cited by 27 publications

(19 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, this approach raises concerns regarding the GF duration, dosage or immune response when they enter into the mammalian body. To solve this issue, current knowledge combines various controlled delivery systems with GFs, such as direct incorporation, layer-by-layer technology or multiphase loading methods, which allow GF release in a sequential and spatiotemporal fashion, leading to GFs being retained by the region of interest with a desirable concentration [ 17 , 22 ]. In addition, the biocompatibility of GF-based delivery systems also needs to be considered because this determines whether they can be applied in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Growth factors-based therapeutic strategies and their underlying signaling mechanisms for peripheral nerve regeneration

et al. 2020

View full text Add to dashboard Cite

Peripheral nerve injury (PNI), one of the most common concerns following trauma, can result in a significant loss of sensory or motor function. Restoration of the injured nerves requires a complex cellular and molecular response to rebuild the functional axons so that they can accurately connect with their original targets. However, there is no optimized therapy for complete recovery after PNI. Supplementation with exogenous growth factors (GFs) is an emerging and versatile therapeutic strategy for promoting nerve regeneration and functional recovery. GFs activate the downstream targets of various signaling cascades through binding with their corresponding receptors to exert their multiple effects on neurorestoration and tissue regeneration. However, the simple administration of GFs is insufficient for reconstructing PNI due to their short half-life and rapid deactivation in body fluids. To overcome these shortcomings, several nerve conduits derived from biological tissue or synthetic materials have been developed. Their good biocompatibility and biofunctionality made them a suitable vehicle for the delivery of multiple GFs to support peripheral nerve regeneration. After repairing nerve defects, the controlled release of GFs from the conduit structures is able to continuously improve axonal regeneration and functional outcome. Thus, therapies with growth factor (GF) delivery systems have received increasing attention in recent years. Here, we mainly review the therapeutic capacity of GFs and their incorporation into nerve guides for repairing PNI. In addition, the possible receptors and signaling mechanisms of the GF family exerting their biological effects are also emphasized.

show abstract

Section: Introductionmentioning

confidence: 99%

Growth factors-based therapeutic strategies and their underlying signaling mechanisms for peripheral nerve regeneration

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To date, the majority of the literature has focused on the production of immobilized GF (iGF) for tissue engineering applications (Lee et al, 2011;Cabanas-Danés et al, 2014;Reed and Wu, 2014;Hajimiri et al, 2015;Wang et al, 2017;Atienza-Roca et al, 2018). Therefore, this review aims to discuss general approaches to immobilize GFs in the context of cell therapy manufacturing.…”

Section: Introductionmentioning

confidence: 99%

Immobilization of Growth Factors for Cell Therapy Manufacturing

Enriquez-Ochoa

Robles-Ovalle

Mayolo‐Deloisa

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cell therapy products exhibit great therapeutic potential but come with a deterring price tag partly caused by their costly manufacturing processes. The development of strategies that lead to cost-effective cell production is key to expand the reach of cell therapies. Growth factors are critical culture media components required for the maintenance and differentiation of cells in culture and are widely employed in cell therapy manufacturing. However, they are expensive, and their common use in soluble form is often associated with decreased stability and bioactivity. Immobilization has emerged as a possible strategy to optimize growth factor use in cell culture. To date, several immobilization techniques have been reported for attaching growth factors onto a variety of biomaterials, but these have been focused on tissue engineering. This review briefly summarizes the current landscape of cell therapy manufacturing, before describing the types of chemistry that can be used to immobilize growth factors for cell culture. Emphasis is placed to identify strategies that could reduce growth factor usage and enhance bioactivity. Finally, we describe a case study for stem cell factor.

show abstract

“…52 Regeneration of wounded tissues and wounded skin depends on the action of a number of factors including RTK ligands, such as EGF (stimulates proliferation and migration of keratinocytes and increases tensile strength of new skin), PDGF (acts as a chemoattractant for mesenchymal cells), FGF (stimulates proliferation, migration and angiogenesis in injured skin), and VEGF (initiates angiogenesis and stimulates proliferation and migration of endothelial cells). 9 Insufficient production of these GFs may diminish regenerative capacity of wounded tissues (Table 2). a Abbreviations: TrkAtropomyosin receptor kinase A; NGFneurotrophic growth factor; EGFepidermal growth factor; PDGFplatelet derived growth factor; EGFR -EGF receptor; PDGFR -PDGF receptor; c-Mettyrosine-protein kinase Met; HGFhepatocyte growth factor.…”

Section: Opto-rtks For Non-neural Tissue Regeneration and Tissue Engimentioning

confidence: 99%

“…It can be achieved by engineering of sophisticated delivery vehicles that are reviewed elsewhere. 9 Recently, two novel technologies to control RTK activity and its downstream signaling with light have been developed. In the rst one, optogenetic control of RTK signaling relies on genetically encoded chimeric proteins, called opto-RTKs, which are engineered to comprise photoreceptors fused to intracellular RTK domains.…”

Section: Introductionmentioning

confidence: 99%